Detalhe da pesquisa
1.
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Breast Cancer Res Treat
; 178(1): 57-62, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31346846
2.
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
J Cell Physiol
; 232(6): 1571-1578, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27861874
3.
Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Genes Chromosomes Cancer
; 55(12): 915-924, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27328445
4.
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
Breast Cancer Res Treat
; 147(3): 599-607, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25234842
5.
The national COVID-19 vaccination campaign targeting the extremely vulnerable: the Florence Medical Oncology Unit experience in patients with cancer.
Eur J Cancer
; 170: 149-157, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35635936
6.
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Clin Breast Cancer
; 20(1): e89-e98, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31378534
7.
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy.
Cancer Chemother Pharmacol
; 84(6): 1219-1227, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31529205
8.
ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.
Front Oncol
; 9: 547, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31297336
9.
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Breast
; 37: 142-147, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29161652
10.
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Cancer Biol Ther
; 19(4): 328-334, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29336662
11.
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
Oncotarget
; 8(34): 56921-56931, 2017 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28915642
12.
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.
Oncotarget
; 7(14): 17932-44, 2016 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26910921